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Abstract: We recently described the synthesis and characterization of a novel difluorinatedbenzylidene analog of
curcumin, commonly referred as CDF, which demonstrated significantly enhanced bioavailability and in vivo anticancer activity. CDF targets many factors similar to curcumin, albeit with more potency, as reported previously.
To further highlight this differential behavior of CDF, we chose matrix metalloproteinase protein MMP-2 which is
involved in the processes of invasion and metastasis of human tumors. Both curcumin and CDF were characterized
for their binding characteristics using in silico docking studies; they were also evaluated via biological assays involving gelatin zymography, miRNA analysis, invasion assays and ELISA. CDF was found to inhibit MMP-2 expression
and activity in A549 and H1299 NSCLC cells much more effectively than curcumin, validating molecular modeling
results. miR-874, an MMP-2-targeting miRNA, was up-regulated by CDF. Thus, it appears that CDF can inhibit MMP-2
through multiple mechanisms. Our results are suggestive of a more potent inhibition of invasion and metastasis by
CDF, compared to curcumin, thus warranting its further evaluation as an effective anticancer agent.
Keywords: MMP-2, CDF, curcumin, miR-874, in silico molecular docking

Introduction
Curcumin (diferuloylmethane) is a nutraceutical
obtained from plant Curcuma longa, which is
commonly used as a spice in tropical Southeast
Asia. It has been extensively investigated for its
putative chemo-preventive and therapeutic
uses. Despite numerous pre-clinical studies
detailing its beneficial effects against various
human cancers, its entry into the clinical practice has been severely limited due to poor bioavailability and rapid metabolism [1]. In an
attempt to overcome such limitations, investigations in our laboratory led to the synthesis of
its novel analog, viz. 3, 4-difluorobenzylidene
curcumin, which is commonly referred to as
CDF. This analog exhibited enhanced bioavailability in pancreatic and other tissues [2, 3].
Subsequent investigations from our laboratory
have also reported on potent regulation of multiple molecular targets such as NF-κB, Akt, COX-

2, IL-6, VEGF, PTEN and miRNAs by CDF [4-8].
Such pleiotropic action of nutraceuticals against multiple therapeutic targets is well-documented [9], and such a multi-targeting effect
could be a good attribute of CDF for the prevention of tumor progression and/or treatment of
human malignancies.
In the present study, we tested whether CDF
can inhibit matrix metalloproteinase-2 (MMP-2),
a member of the family of metalloproteinases.
Members of this family are involved in the degradation of extracellular matrix facilitating the
process of metastasis, and thus MMP-2 is an
important target to inhibit invasion and metastasis. An increased expression of MMP-2 has
been reported in various tumors including ovarian, breast and prostate tumors as well as melanoma [10]. Studies in recent years have suggested a role of MMP-2 as cancer prognostic
marker [11] which is associated with poor prog-
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nosis [12]. In order to validate MMP-2 as a target of CDF, docking studies were performed to
assess the activity of CDF versus curcumin
through MMP-2 crystal structure. CDF activity
was compared to that of curcumin, its parent
compound. Subsequently, biological assays
were performed and compared for CDF and
curcumin using gelatin zymography, invasion
and ELISA techniques. We observed a positive
correlation between docking studies and biological assays validating the use of our integrated approach to find new molecular target of
CDF as a novel anticancer agent.
Materials and methods
Cell lines and reagents
The human lung adenocarcinoma cell lines
A549 and H1299 were purchased from the
American Type Culture Collection (Manassas,
VA) and maintained according to the American
Type Culture Collection’s instructions. Cells were cultured in 5% CO2-humidified atmosphere at
37°C. The cell lines have been tested and
authenticated through the core facility (Applied
Genomics Technology Center at Wayne State
University) by short tandem repeat profiling
using the PowerPlex 16 System from Promega.
Docking studies
The NMR structure of MMP-2 protein PDB id:
1HOV available at Protein databank [13] was
used for docking of CDF and curcumin. Molecular docking was carried out using Auto Dock
4.2 software program [14]. This protein contains 11 models of macromolecules and previous studies have reported no differences in the
docking studies using all 11 models. Hence,
the catalytic domain containing S1’, S1, S2’, S3’
of the model 1 of PDB id 1HOV was selected for
docking study [15]. The docking parameters
were optimized through self-docking exercise
carried out using the co-crystallized ligand.
Polar hydrogen atoms were added followed by
assignment of Kollman united atom charge to
MMP-2. All rotatable bonds within the ligand
were allowed to rotate freely and the molecule
was considered rigid. For the zinc ion, the parameter set reported by Stote and group was
used (r=1.1 A, e=0.25 kcal mol-1 and a formal
charge of +2e) [16]. AutoGrid program was
used to generate 3D affinity grid fields with grid
map of 40 × 40 × 40 points with spacing of
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0.375 Å. AutoDock tools utility was used to generate both grid and docking parameter files
(i.e., gpf and dpf). Docking parameters were set
to 25 automated runs for a 150 population size
with a 2,500,000 maximum number of energy
evaluations for each docking experiment with
Lamarckian genetic algorithm as the search
method. The Lamarckian Genetic Algorithm
(LGA) was used as the search engine keeping
other parameters to default value [17]. About
25 conformations for curcumin and CDF were
generated. The interactions of docked complex
MMP-2 protein-ligand conformations, including
hydrogen bonds and the bond lengths were
analyzed using PyMOL v0.99rc6 [18]. The docking studies were performed at Tata Consultation
Services, Pune.
miRNA transfections
Transfections of pre-miR-874 in A549 and
H1299 cells were done using methodology previously described [19]. Briefly, cells were seeded (2.5 × 105 cells per well) in six well plates
and transfected with pre-miR-874 or non-specific (NS) pre-miRNA controls (Life Technologies)
at a final concentration of 200 nM, using
DharmaFECT transfection reagent (Dharmacon). After 48 hours of transfection, cells were
passaged and transfected once again before
evaluating the levels of target (MMP-2) by realtime RT-PCR.
MMP-2 zymography
Activity of MMP-2 was assessed in the culture
supernatants by gelatin zymography. A549 and
H1299 cells were first exposed to vehicle control or curcumin/CDF (10 µM) for 72 hours. At
the end of incubation, 50 µl of culture supernatant was mixed with sample buffer and resolved
on a 12% SDS-PAGE under non-reducing conditions. The gel was co-polymerized containing
0.5 mg/ml of gelatin (Sigma, St. Louis, USA).
Gel was washed twice for 30 minutes with
renaturation buffer (2.5% Triton X-100) at room
temperature before incubation in the incubation buffer (50 mM Tris-HCl pH7.5, 200 mM
NaCl, 10 mM CaCl2, 1 μM ZnCl2) at 37°C for 16
hours. Thereafter, gel was stained for 2 hours
in 0.25% coomassie brilliant blue R-250 and
then de-stained. White bands were observed
against a blue background after de-staining,
indicating MMP-2’s gelatinolytic activity.
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Figure 1. Binding of curcumin and CDF in the active site of MMP-2 protein cavity as assessed by molecular docking.
A. The surface view of docking of curcumin (blue) in the catalytic cavity of MMP-2; it interacts with Zn seen as ball
and Arg 149 forming hydrogen bonds. It can be seen that curcumin extends in the S1’ pocket. B. The docking of
curcumin (blue) in MMP-2 protein shown in cartoon form with the secondary structure of protein visible. The interaction with Zn and Arg 149 can be seen. Arg 149 is shown as lines. C. The surface view of docking of CDF (magenta)
in the catalytic cavity of MMP-2; the interaction of CDF with residues Leu 83, Ala 84 and His 120 forming hydrogen
bonds can be seen. Zn atom is seen as ball. It can be seen that CDF extends in the S1’ pocket. D. The docking of CDF
(magenta) in MMP-2 protein shown in cartoon form with the secondary structure of protein visible. The interaction
with residues Leu 83, Ala 84 and His 120 can be seen. The interacting residues are shown as lines.

Real-Time RT-PCR

Figure 2. The cartoon view of superimposed image
curcumin (yellow) and CDF (cyan) in the catalytic domain of MMP-2 protein.
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Real-Time RT-PCR analyses were done as
described previously [20]. Total RNA was isolated using Trizol reagent (Life Technologies)
according to the manufacturer’s instructions.
Real-time PCR was used to quantify mRNA
expression and the amount of RNA was normalized to GAPDH expression. For miRNA analysis,
total RNA was isolated using the mirVana
miRNA isolation kit (Life Technologies). The levels of miRNAs were determined using miRNAspecific Taqman probes from the Taqman
MicroRNA Assay (Life Technologies). The relative amounts of miRNA were normalized to
RNU48.
Am J Transl Res 2015;7(2):298-308
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Table 1. Docking analysis and consensus scores of Curcumin and CDF
in the active site of MMP-2 protein assessed by computer modeling
studies
Compound
Curcumin
CDF

Minimum Binding No of hydrogen
energy (Kcal/mol)
bonds
-7.35
2
-6.39

4

Amino acid Hydrogen bond
interacting
Distance (Å)
Arg 149 (H)
2.5
Zn
1.9
Leu 83 (HN)
2.0
Ala 84 (HN)
1.8
Ala 84 (O)
1.8
His 120 (HN)
2.1

Cell invasion assay
Cell invasion assay was performed using 24
well transwell permeable supports with 8 µM
pores (Corning) [20]. After treatment of cells
with curcumin/CDF or the DMSO vehicle (control) for indicated times, cells were suspended
in serum free medium and seeded into the
transwell inserts coated with growth factor
reduced Matrigel (BD Biosciences). Bottom
wells were filled with complete media. After 24
hours, cells were stained with 4 µg/ml calcein
AM (Life Technologies) in PBS at 37°C for 1 h.
Cells were detached from inserts by trypsinization and fluorescence of the invaded cells was
read in ULTRA Multifunctional Microplate Reader (TECAN, San Jose, CA).
MMP-2 activity assay
The activity of MMP-2 was further assayed
using human MMP-2 ELISA kit (Invitrogen, USA)
following the vendor’s protocol. The assay is
based on solid phase sandwich ELISA wherein
a highly purified antibody specific for MMP-2 is
coated onto the wells of the microtiter strips
purchased from the vendor. During the first
incubation, standards of known MMP-2 content, controls, and assay samples were pipetted into the coated wells. A biotinylated secondary detection antibody was added after washing followed by further washing and addition of
streptavidin-peroxidase enzyme bound to the
biotinylated antibody to complete four-member
sandwich. After a third incubation and washing
to remove all unbound enzyme, the substrate
solution was added. The bound enzyme acted
upon the substrate to produce color which was
read at 450 nM using ULTRA Multifunctional
Microplate Reader (TECAN, San Jose, CA). The
intensity of the color was directly proportional
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to the concentration of
MMP-2 present.
Results
MMP-2 as a molecular
target

To evaluate binding stabilities of curcumin and
CDF in the protein cavity
of MMP-2, we first assessed the binding of a
standard compound in
the pre-defined active site of MMP-2 protein by
using Autodock software program. The active
site of MMP-2 protein consists of Zn and consensus (HEBGHXLGLXHS) of amino acids for Zn
binding motif which are conserved throughout
the MMPs and contain three histidine residues
which are bound to Zn [21]. Previous reports
have suggested that amino acids in the catalytic cavity play an important role in binding of
inhibitor in the protein cavity [15, 22, 23]. The
protein cavity containing Zn and important
amino acids was selected for docking of curcumin and CDF. Both compounds were found to
dock into the active site of MMP-2 protein cavity with a good fit (Figures 1, 2 and Table 1). The
aryl hydroxyl group of CDF was found to be
involved in two hydrogen bonding interactions
with Ala 84 (both 1.8 Å) and one with Leu 83
(2.0 Å), while one of the central diketo group
interacted with His 120 (2.1 Å). These residues
are found to be similar with those involved in
the binding of known inhibitors of MMP-2 [15,
22] and hence CDF is anticipated to exhibit pronounced inhibition of MMP-2. On the other
hand the binding interactions of curcumin are
substantially different wherein one of the hydroxyl groups on the side aryl ring is found to be
involved in H-bonding with Arg 149 (2.5 Å) while
the methoxy group on the other aryl ring is
found to interact with Zn (1.9 Å) atom. Although
these interactions yield stronger binding energy
for curcumin (minimum binding energy: -7.35
Kcal/mol) than CDF (minimum binding energy:
-6.39 Kcal/mol), such binding is not expected
to influence MMP-2 inhibition, confirmation of
which is provided by the proceeding assays.
Inhibition of MMP-2 activity
In order to explore the inhibition of MMP-2
activity, we chose A549 and H1299 lung can-
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Figure 3. MMP-2 gelatinolytic activity (zymography) comparing the effects of curcumin and its derivative CDF. A549
and H1299 lung cancer cells were exposed to vehicle control (DMSO) or 10 µM curcumin/CDF for 72 hours. The
collected conditioned medium was subjected to zymography (upper panel). Densitometric analysis was performed
on the bands from zymography gel (lower panel) where the band from control DMSO-treated sample was assigned a
value of 1.0 and the intensity of curcumin- and CDF-treated samples’ bands was calculated relative to control band.

cer cells as our models because these cells are
known to express MMP-2 [24, 25]. We first performed gelatin zymography to directly test the
ability of curcumin and CDF to modulate the
expression of MMP-2. Cells were treated with
either vehicle control or 10 µM solutions of the
two compounds. Cultures from these treated
cells were then collected and subjected to
zymography. We found that treatment with CDF
more effectively inhibited the activity of MMP-2
(Figure 3). A densitometric analysis of the
bands revealed 16% inhibition of MMP-2 activity by curcumin and 80% inhibition by CDF in
A549 cells (Figure 3). CDF was observed to be
a potent inhibitor of MMP-2 activity in H1299
cells, as well, with 82% inhibition, compared to
58% inhibition by curcumin (Figure 3).
Transcriptional regulation of MMP-2 activity
To evaluate whether curcumin/CDF could transcriptionally regulate MMP-2, we quantitated
MMP-2 mRNA by real-time RT-PCR after treating A549 and H1299 cells with these com-
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pounds for 72 hours. While curcumin inhibited
the MMP-2 mRNA by ~23% in A549 and 30% in
H1299 cells, the inhibition by CDF was significantly more (p < 0.01) in both the cell lines
tested- ~40% in A549 cells and 51% in H1299
cells (Figure 4A). Regulatory effect of mRNA
transcripts often involves miRNAs. miR-874
has been reported to regulate MMP-2 levels in
A549 and H1299 cells [25], therefore, we evaluated the levels of this tumor-suppressive
miRNA in curcumin/CDF-treated cells. Both,
curcumin and CDF were found to up-regulate
miR-874 (Figure 4B) but the up-regulation by
CDF was significantly more. As a proof of concept, we transfected A549 and H1299 cells
with pre-miR-874 and observed down-regulation in the expression of its target MMP-2
(Figure 4C), thus validating the regulation of
MMP-2 by miR-874 in our model system.
Biological significance of such MMP-2 inhibition was evaluated by invasion assays, and
while both curcumin and CDF inhibited the invasion of A549 and H1299 cells (Figure 4D), CDF
again showed as a more potent compound.
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Figure 4. Transcriptional regulation of MMP-2. A549 and H1299 cells were treated with 10 µM curcumin/CDF for
72 hours and the MMP-2 mRNA transcripts (A) or the miR-874 levels (B) were quantitated by Real-Time RT-PCR.
(C) MMP-2 mRNA levels were also measured after the cells were transfected with pre-miR-874 (NS, non-specific
pre-miRNA control). Finally, A549 and H1299 cells treated with curcumin/CDF were subjected to invasion assays
by plating cells in matrigel-coated inserts. The invading cells were collected by trypsinization and their fluorescence
was quantitated using plate reader.

Thus, MMP-2 inhibition was correlated with the
inhibition of invasive potential of both the cell
lines.
Quantitative analysis of MMP-2 activity inhibition
We assayed the secreted MMP-2 using quantitative ELISA assay. A549 and H1299 cells were
first exposed to increasing concentrations of
curcumin and CDF for 72 hours and then
MMP-2 levels were assayed in the culture
supernatants. As seen in Figure 5, CDF inhibited the secretion of MMP-2 to a greater extent
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than curcumin, at all the concentrations tested.
At the highest tested concentration of 10 µM,
inhibition by curcumin was ~25% and ~85% by
CDF, in A549 cells. In H1299 cells, inhibitions
were ~39% and ~83%, respectively. Using this
dose of 10 µM, we also tested a time-dependent inhibition of MMP-2 by curcumin and CDF.
Aliquots of conditioned media were collected at
the indicated time periods and subjected to
ELISA. CDF was found to be much more effective in down-regulating MMP-2 secretion, compared to curcumin, at all the time periods and
in both the cell lines (Figure 6).
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Figure 5. Concentration-dependent inhibition of MMP-2 secretion. A549 cells and H1299 were treated with indicated doses of curcumin/CDF or the equivalent quantities of DMSO (vehicle control). Treatment was carried out for
72 hours and then the samples were subjected to MMP-2 ELISA.

Figure 6. Time-course inhibition of MMP-2 secretion. A549 cells and H1299 were treated with 10 µM doses of
curcumin/CDF or the equivalent quantities of DMSO (vehicle control) for indicated time periods. Conditioned media
was collected at the end of different time-points and stored at -80°C until ready to be assayed. Once all the samples
were collected, they were subjected to MMP-2 ELISA.

Discussion
Whenever a novel anticancer compound is synthesized that exhibits promising cytotoxic
effects against cancer cell lines, the first and
foremost challenge is to elucidate its molecular
targets that are associated with its biological
activity. This is true even for the compounds
that are analogs of established and extensively
studied phytochemicals. In the present study,
we tested MMP-2 as a protein target of CDF,
which is a novel and potent analog of curcumin.
MMP-2 is an enzyme that belongs to the family
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of matrix metalloproteinases which are calcium-dependent, zinc-containing endopeptidases [26, 27]. The family of human MMPs consists of 23 different forms that are divided into
six groups but are structurally and functionally
related [27]. They are secreted in an active/
inactive zymogen or a pro-MMP form. MMP-2
belongs to the gelatinase group of MMPs, which
also comprises of MMP-9. This group is so
named because these two MMPs primarily
digest gelatin, the denatured form of collagen.
In the present study, activity of MMP-2 was
analyzed by a technique called substrate
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zymography. This technique identifies MMP-2
through the degradation of its preferential substrate gelatin on a polyacrylamide gel, and is
particularly sensitive since it can detect levels
of MMP-2 as low as 10 pg [28]. While zymography is a reliable technique to study functional
MMP-2s, it is not necessarily very quantitative,
and hence we also employed ELISA technique
for its quantitation. Inhibition of MMP-2 activity
was determined to be 16% by zymography and
25% by ELISA in case of curcumin while it was
found to be 80% by zymography and 85% by
ELISA for CDF.
The compounds used for MMP inhibition usually contain zinc binding or chelating groups like
hydroxymate, carboxylate, phosphinate and thiolate, respectively [29]. It has been observed
that the hydroxymate group has unfavorable
pharmacokinetics and is associated with toxicities [29, 30]. Thus, new group of compounds
need to be evolved as MMPs inhibitors. Based
on the present work we should like to propose
that phytochemical curcumin and its difluobenzylidene analog CDF are the novel MMP-2 inhibitors. Although Zn chelation is generally considered as a requirement for MMP inhibitors, the
interactions with key amino acid residues in the
catalytic site are also of foremost importance
for influencing the inhibitory activity [31]. In
fact, there are reports documenting that MMP13 inhibitors do not interact with Zn center,
suggesting that Zn chelation is not the only criteria for inhibition of MMP’s [30, 32]. The interactions with the hydrophobic pocket S1’ is also
found to be crucial for inhibiting MMP-2 [30,
33].
Analyzing the present docking results reveals
that both CDF and curcumin bind to the MMP-2
in similar way as the co-crystal compound i52
going through the S1’ pocket containing hydrophobic residues Phe 148, Phe 115, Thr145
and Leu150. However, CDF showed interactions with Leu 83 (S3’pocket) and Ala 84(S1
pocket) similar to the interactions in the cocrystal structure of hydroxamic acid inhibitor
i52. The Ala 84 is a highly conserved residue in
the active site of MMP protein, and thus interaction with this residue is considered crucial
[15]. The active site also contains three histidine residues (His 120, His124 and His 130)
bound to the Zn atom which are highly conserved in MMPs. In the present case, CDF was
found to form hydrogen bond with His 120
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which is helpful in anchoring the compound in
the active site near Zn atom while extending
itself into the S1’ hydrophobic pocket analogous to the known co-crystal inhibitor. These
interactions similar to other known MMP-2
inhibitors along with anchorage in the S1’ pocket may help explain the specificity of CDF for
MMP-2 protein [15, 29, 34]. On the contrary,
curcumin did not exhibit any interactions with
the important residues although it interacted
with Zn through its enolic hydroxyl group, resulting in high binding energy which alone may not
be important for the MMP-2 inhibitory activity.
Additionally, curcumin did show H-bonding
interaction with Arg149 but in the neighboring
pocket [15]. Such differential interactions with
the important amino acid residues seem to provide the basis for the potent MMP-2 inhibitory
activity of CDF compared to curcumin despite
having lower binding energy in the docking site.
Molecular docking studies are indicative of a
post-translation regulation of target protein by
anticancer agents. The inhibition of MMP-2
activity by curcumin and CDF seems to stem
from their ability to interact with the specific
regions on the protein surface, as described
above. Interestingly, we also observed a transcriptional regulation of MMP-2 by curcumin
and CDF which suggests the regulation of
MMP-2 at multiple steps. As a mechanism, an
up-regulation of miR-874 was observed. miR874 is a tumor suppressive miRNA [35] which
has been shown to target MMP-2 in exactly the
same NSCLC cell lines [25] as used in the present study, namely A549 and H1299. Similar to
our current observations, this study [25] also
reported an inhibition of MMP-2 in pre-miR874-transfected cells. Further, this study also
evaluated an in vivo effect of miR-874 up-regulation wherein pre-miR-874 treated A549 cells
showed much reduced orthotopic tumor burden when implanted intra-thoracic in athymic
nude mice. Combined with the invasion assays
described by us, there is a clear biological relevance of MMP-2 regulation in the NSCLC cells.
Previous work from our laboratory has shown
an action of CDF against membrane type 1metalloproteinase (MT1-MMP), also known as
MMP-14 [8]. CDF was observed to down-regulate MT1-MMP through a mechanism that
involved up-regulation of microRNA-200s (miR200s) and PTEN. It is interesting to note that
MT1-MMP is involved in the activation of MMP-2
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[36-38] and, thus, CDF influences multiple
steps in MMP-2 activation cascade by interacting with MT1-MMP as well as MMP-2. The miR200s are markers of epithelial phenotype.
Another epithelial marker E-cadherin has recently been connected to MMP-2 and invasion
of A549 NSCLC cells, especially because the
loss of E-cadherin was shown to promote invasion in an MMP-2-dependent manner [39]. For
that reason, we initially used A549 cells in the
current study as a model for the inhibition of
MMP-2 activity. In order to rule out cell line specific effects, and also to study the transcriptional regulation involving miR-874, as reported
earlier [25], we corroborated our results in another NSCLC cell line, H1299. The available literature indicate a nexus of MT-MMP, MMP-2,
miR-200s and EMT driving the processes of
invasion and metastasis, and our current study
indicates attenuation of such nexus by CDF,
along with a novel regulation involving miR-874,
a revelation that needs to be tested further in
future studies.
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